SYGNIS AG Signs Supply Agreement with US Biological for the Lightning-Link Antibody Labelling Technology
News Nov 28, 2017
Heikki Lanckriet, CEO and CSO of SYGNIS AG, commented: “We are delighted that US Biological has chosen Lighting-Link® as its preferred method for antibody labelling. The technology has clear advantages in terms of simplicity and reproducibility, which will ultimately benefit US Biological’s customers by increasing the range of products available.”
US Biological is a global manufacturer and distributor of bioreagents, offering world-wide distribution of over 1,000,000 antibodies, biochemicals, biologicals, cell culture media, research kits and molecular biology bioreagents. The Company will use Lightning-Link as its preferred antibody conjugation technology to expand its existing catalogue by enabling the production of additional labels, and allowing the company to address a broader range of markets. In addition to core labels for the Lightning-Link range (horseradish peroxidase, alkaline phosphatase, and Fluorescein), the agreement gives US Biological the option to access the full range of Innova-branded products, including Europium and gold nanoparticles.
Lightning-Link antibody and protein labelling technology provides the world’s fastest, easiest to use and most efficient method of antibody conjugation, offering highly stable antibody and protein conjugation with only 30 seconds hands-on time, and no separation steps. Lightning-Link can make a range of assays easier, quicker and more sensitive, and contribute to reduced project costs. Lightning-Link technology offers consistently high quality and easy scalability, with excellent batch-to-batch reproducibility, leading to reduced manufacturing costs.
The Discovery of Typhoid Toxin's Sweet Tooth Could Lead to New TreatmentsNews
"Our study shows that the typhoid toxin targets both the immune system and central nervous system... This represents a new paradigm in the infectious agents' incursion of the host." The new study shows how the toxin exclusively damages selected cells at the organism level, specifically seeking cells that express particular sugars because of their binding abilities.READ MORE
Single-Dose Vaccine Could Provide Faster Protection in Cholera EpidemicsNews
Each year there are more than three million cases of cholera worldwide, a disease transmitted through contaminated food and water that hits developing countries particularly hard. While the standard regimen for protecting against cholera with existing non-living oral cholera vaccines includes administering two doses over a two-week period, research now shows that giving a stronger single-dose of a live oral vaccine could be an effective tool in controlling outbreaks more quickly.READ MORE
Severity of Autoimmune Disease Influenced by Time of DayNews
Insights into how the body clock and time of day influence immune responses are revealed today. Understanding the effect of the interplay between 24-hour day-night cycles and the immune system may help inform drug-targeting strategies to alleviate autoimmune disease.